QuantLogix ← MDT scorecard
📅 MDT Earnings Preview
Medtronic plc
Next report (est.)
12/07/2026
Countdown
40 days
EPS growth YoY
+40.7%
Revenue growth YoY
+13.7%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
09/03/2026 ±2.8% +1.0% over-priced
06/18/2026 ±2.3% +1.5% over-priced
02/24/2026 ±2.5% -1.9% over-priced
11/25/2025 ±3.2% +2.1% over-priced
08/26/2025 ±3.4% +0.1% over-priced
06/20/2025 ±1.7% +0.7% over-priced
02/25/2025 ±3.7% +0.3% over-priced
11/26/2024 ±2.2% -0.1% over-priced
Across these reports, options implied an average ±2.7% move vs an actual average of 1.0% — the stock stayed inside the implied band 100% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2027 $1.14 $9.8B $1.5B
Q4 FY2026 — $9.8B $1.2B
Q3 FY2026 $0.89 $9.0B $1.1B
Q2 FY2026 $1.07 $9.0B $1.4B
Analyst posture
Buy / Strong Buy
22
Hold
11
Sell
0
Stable: -2 net change 30d
Live 5-factor engine read: Buy · 67/100 Full scorecard →
Get alerted before every MDT report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on MDT before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Medtronic plc (MDT) reports in 40 days, with the next report estimated for 12/07/2026. Across the last 8 reports, options priced an average ±2.7% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced MDT's earnings risk. Fundamentals into the print: EPS up 40.7% year-over-year, revenue up 13.7%. QuantLogix's live 5-factor engine currently reads MDT as a buy at 67/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →